flavopiridol

Indications: - relapsed chronic lymphocytic leukemia (CLL) Dosage: - bolus flavopiridol followed by 4-hour flavopiridol infusion weekly for 3 weeks (28-day cycle) - prophylactic dexamethasone with each flavopiridol dose - rasburicase before the first two doses of flavopiridol to prevent tumor lysis syndrome - pegfilgrastim with each cycle - antimicrobial prophylaxis throughout course of treatment Adverse effects: 1) most common: (all >90%) a) neutropenia b) diarrhea c) fatigue d) abnormal liver function tests 2) less common a) tumor lysis syndrome (44%), b) cytokine release syndrome (42%) c) infections despite prophylactic antibiotics (25%) Mechanism of action: - cyclin-dependent kinase inhibitor

General

antineoplastic agent (chemotherapeutic agent) enzyme inhibitor

References

- Lin TS et al Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009 Dec 10;27(35):6012-8. Epub 2009 Oct 13. PMID: 19826119 http://dx.doi.org/10.1200/JCO.2009.22.6944